Expert Profile: steendl | Research Directory

Education

Medical Degree: Robert Wood Johnson Medical School 2005

Masters of Sciences: Harvard School of Public Health 2014 (Epidemiology)

Internal Medicine Residency: Jackson Memorial Hospital 2008

Cardiovascular Disease Fellowship: Jackson Memorial Hospital 2011

Clinical Research Fellowship: T.I.M.I. Study Group, Harvard University 2014

Undergraduate Degree: Cook College, Rutgers University New Brunswick, NJ, 2000

Certifications

American Board of Internal Medicine (Cardiovascular Disease) (Certification Date: 11-02-2012 ) - (Recertification Date: to 12-29-2022 )

Clinical Interests

Cardiology

Cardiovascular Disease

Obesity

Shortness of Breath

Specialities

Cardiovascular Disease

Echocardiography

Internal Medicine

Nuclear Cardiology

Research Support

Grant: #URS Strategic Collaborative Grants AY2017-2018 Investigators:Steen, Dylan 05-01-2018 -10-31-2019 UC's Research Support SUPERmaket and Web-based Inerventions targeting Nutrition for CVD Risk Reduction (SUPERWIN) Role:PI $97,336.00 Active Level:Internal UC

Grant: #R40217 Investigators:Steen, Dylan 07-01-2020 -12-31-2021 UC's Collaborative Research Advancement Grant Program - Track 1: Pilot Teams SUPERmarket and Web-based Intervention targeting Nutrition (SuperWIN) for CVD Risk Reduction Role:PI $25,000.00 Active Level:Internal UC

Grant: #CKJX839B12302 10-04-2021 -10-04-2024 Novartis AG A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease... Role:PI 319472.19 Hold Level:Industry

Grant: #AROAPOC3-3003 SHASTA 10-28-2024 -10-27-2027 IQVIA Clinical Trial Payments DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY) Role:PI 312823.54 Hold Level:Industry

Grant: #MUIR-3 AROAPOC3-3009 11-08-2024 -11-07-2027 IQVIA Clinical Trial Payments DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (MUIR-3 STUDY Role:PI 1208245.62 Hold Level:Industry

Publications

Peer Reviewed Publications

O'Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP. (2014. ) Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.JAMA, , 312 (10 ) ,1006-15 More Information

Steen, Dylan L; Bhatt, Deepak L (2014. ) Statin potency associated with incident diabetes in a real-world evaluation.Evidence-based medicine, , 19 (2 ) ,68 More Information

Steen, Dylan L; O'Donoghue, Michelle L (2013. ) Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events.Cardiology and therapy, , 2 (2 ) ,125-34 More Information

Steen, Dylan L; Cannon, Christopher P; Lele, Suhas S; Rajapurkar, Mohan M; Mukhopadhyay, Banibrata; Scirica, Benjamin M; Murphy, Sabina A; Morrow, David A (2013. ) Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.Clinical cardiology, , 36 (3 ) ,139-45 More Information

Hebert, Kathy; Quevedo, Henry C; Tamariz, Leonardo; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M (2012. ) Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, , 17 (2 ) ,113-22 More Information

Steen, Dylan L; Cannon, Christopher P (2012. ) Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Reviews in cardiovascular medicine, , 13 (1 ) ,e48-51

Hebert, Kathy; Lopez, Barbara; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M Prevalence of electrocardiographic abnormalities in a systolic heart failure disease management population by race, ethnicity, and sex.Congestive heart failure (Greenwich, Conn.), , 16 (1 ) ,21-6 More Information

Steen, D.L. (2014. ) The Revised ACC/AHA/HRS Guidelines for the Management of Patients With Atrial Fibrillation. http://anticoagulation.cardiosource.org. September 25, 2014. Accessed Oct 2, 2014. http://anticoagulation.cardiosource.org/Hot-Topics/2014/09/Revised-Guidelines-for-the-Management-of-Patients-With-Atrial-Fibrillation.aspx .

Steen D.L,, O’Donoghue M.L. (2013. ) Inhibitors for the Reduction of Cardiovascular Events. Cardiology and Therapy. Cardiology and Therapy, , 2 (2 ) ,125

Steen D.L. (2013. ) A Middle-Aged Man With AFib and Mechanical Heart Valve. .http://anticoagulation.cardiosource.org, ,

Steen DL, Khera AV, Cannon CP (2013. ) Anacetrapib: Potential for the prevention and treatment of coronary heart disease. Research Reports in Clinical Cardiology, , 4 ,39

Steen DL, Wiviott SD, Cannon CP (2012. ) HDL and CETP Inhibition .http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/2012/02/HDL-and-CETP-Inhibition.aspx, ,

Hebert K, Dias A, Franco E, Tamariz L, Steen D, Arcement LM (2011. ) Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program. .Congestive Heart Failure, , 17 (6 ) ,309

Contact Information

Academic - Internal Medicine
Medical Sciences Building Room 6065
Cincinnati Ohio, 45267
Phone: 513-558-1067
dylan.steen@uc.edu

Dylan Lauri Steen , MD

Adjunct Associate Professor

Director of Clinical Trials and Population Health Research, UC Heart, Lung and Vascular Institute